Premiere Date: September 20, 2019
Expiration Date: March 20, 2021
This activity offers CE credits for:
1. Physicians (CME)
All other clinicians either will receive a CME Attendance Certificate or may choose any of the types of CE credit being offered.
The goal of this activity is to provide an understanding of the effects on the CNS that lead to HIV-associated neurocognitive disorders (HAND).
At the end of this CE activity, participants should be able to:
• Discuss the criteria for the three stages of HAND
• Explain the pathophysiology of HAND
• Describe the challenges associated with the diagnosis of HAND
• Communicate the role of combination antiretroviral therapy in HAND
This continuing medical education activity is intended for psychiatrists, psychologists, primary care physicians, physician assistants, nurse practitioners, and other health care professionals who seek to improve their care for patients with mental health disorders.
CME Credit (Physicians): This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CME Outfitters, LLC, and Psychiatric Times. CME Outfitters, LLC, is accredited by the ACCME to provide continuing medical education for physicians.
CME Outfitters designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note to Nurse Practitioners and Physician Assistants: AANPCP and AAPA accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer-review process.
The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Francisco González-Scarano, MD, has no disclosures to report.
Dennis L. Kolson, MD, PhD, has no disclosures to report.
Vivek Datta, MD (peer/content reviewer), has no disclosures to report.
Applicable Psychiatric Times staff and CME Outfitters staff have no disclosures to report.
UNLABELED USE DISCLOSURE
Faculty of this CME/CE activity may include discussion of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, and the faculty do not endorse the use of any product outside of the FDA-labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
For content-related questions email us at [email protected]; for questions concerning CME credit call us at 877.CME.PROS (877.263.7767)
Dr González-Scarano is Professor Emeritus of Neurology and Dr Kolson is Professor of Neurology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA.
1. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69:1789-1799.
2. Grant I, Franklin DR Jr, Deutsch R, et al, for the CHARTER Group. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014;82:2055-2062.
3. Robertson KR, Jiang H, Kumwenda J, et al. HIV Associated neurocognitive impairment in diverse resource limited settings. Clin Infect Dis. Sept 13, 2018; Epub ahead of print.
4. Saylor D, Dickens AM, Sacktor N, et al. HIV-associated neurocognitive disorder: pathogenesis and prospects for treatment. Nat Rev Neurol. 2016;12:234-248.
5. Navia BA, Cho ES, Petito CK, Price RW. The AIDS dementia complex: II. Neuropathology. Ann Neurol. 1986;19:525-535.
6. Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17:3-16.
7. Heaton RK, Clifford DB, Franklin Jr DR, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology. 2010;75:2087-2096.
8. Heaton RK, Franklin Jr DR, Deutsch R, et al. Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clin Infect Dis. 2015;60:473-480.
9. Clifford DB, Ances BM. HIV-associated neurocognitive disorder. Lancet Infect Dis. 2013;13:976-986.
10. Sturdevant CB, Joseph SB, Schnell G, et al. Compartmentalized replication of R5 T cell-tropic HIV-1 in the central nervous system early in the course of infection. PLoS Pathog. 2015;11:e1004720.
11. Carroll A, Brew B. HIV-associated neurocognitive disorders: recent advances in pathogenesis, biomarkers, and treatment. F1000Res. 2017;6:312.
12. Burdo TH, Lackner A, and Williams KC. Monocyte/macrophages and their role in HIV neuropathogenesis. Immunol Rev. 2013;254:102-113.
13. Calcagno A, Di Perri G, Bonora S. Treating HIV infection in the central nervous system. Drugs. 2017;77:145-157.
14. Brew BJ. Benefit or toxicity from neurologically targeted antiretroviral therapy? Clin Infect Dis. 2010;50:930-932.
15. Peluso MJ, Meyerhoff DJ, Price RW, et al. Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis. 2013;207:1703-1712.
16. Caniglia EC, Cain LE, Justice A, et al. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology. 2014;83:134-141.
17. Klasse PJ, Moore JP. Is there enough gp120 in the body fluids of HIV-1-infected individuals to have biologically significant effects? Virology. 2004;323:1-8.
18. Bougea A, Spantideas N, Galanis P, et al. Optimal treatment of HIV-associated neurocognitive disorders: myths and reality: a critical review. Ther Adv Infect Dis. 2019;6:2049936119838228.; eCollection.
19. Dube B, Benton T, Cruess DG, Evans DL. Neuropsychiatric manifestations of HIV infection and AIDS. J Psychiatry Neurosci. 2005;30:237-246.
20. Gaskill PJ, Calderon TM, Coley JS, Berman JW. Drug induced increases in CNS dopamine alter monocyte, macrophage and T cell functions: implications for HAND. J Neuroimmune Pharmacol. 2013;8:621-642.
21. Scott JC, Woods SP, Matt GE, et al. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev. 2007;17:275-297.
22. Mimiaga MJ, Pantalone DW, Biello KB, et al. An initial randomized controlled trial of behavioral activation for treatment of concurrent crystal methamphetamine dependence and sexual risk for HIV acquisition among men who have sex with men. AIDS Care. 2019:1-13.
23. Reback CJ, Fletcher JB, Leibowitz AA. Cost effectiveness of text messages to reduce methamphetamine use and HIV sexual risk behaviors among men who have sex with men. J Subst Abuse Treat. 2019;100:59-63.
24. Liang H, Wang X, Chen H, et al. Methamphetamine enhances HIV infection of macrophages. Am J Pathol. 2008;172:1617-1624.
25. Portilla I, Reus S, Leon R, et al. Neurocognitive impairment in well controlled HIV-infected patients: a cross sectional study. AIDS Res Hum Retroviruses. 2019;35:634-641.
26. Gisslen M, Price RW, Andreasson U, et al. Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine. 2016;3:135-140.
27. Fazeli PL, Casaletto KB, Paolillo E, et al for the HNRP Group. Screening for neurocognitive impairment in HIV-positive adults aged 50 and older: Montreal Cognitive Assessment relates to self-reported and clinician rated everyday functioning. J Clin Exp Neuropsychol. 2017;39:842-853.
28. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration effectiveness rank for qualifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65:65.
29. Joseph SB, Kincer LP, Bowman NM, et al. HIV RNA detected in the CNS after years of suppressive antiretroviral therapy can originate from a replicating CNS reservoir or clonally expanded cells. Clin Infect Dis. Dec 2018; Epub ahead of print.
30. Tiberio PJ, Ogbuagu OE. CD8 T-cell lymphocytosis and associated clinical syndromes in HIV-infected patients. AIDS Rev. 2015;17:202-211.
31. May MT, Gompels M, Delpech V, et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS. 2014;28:1193-1202.
32. Sheppard DP, Ludicello JE, Bondi MW, et al. Elevated rates of mild cognitive impairment in HIV disease. J Neurovirol. 2015;21:576-584.